BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics Inc., a biotechnology company that translates the novel science of condensates into breakthrough therapeutics, today announced that it was awarded a Target ALS Foundation grant, in collaboration with the ALS Association and The Jackson Laboratory, for an in vivo proof-of-concept study of c-mods in a chronic C9orf72 repeat, the most common genetic cause of ALS.

See the original post here:
Dewpoint Therapeutics Awarded Target ALS Grant for Development of C-mods for ALS